No Data
No Data
No Data
No Data
No Data
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
REDWOOD CITY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ((Coherus, NASDAQ:CHRS) today announced the first presentation of clinical data for CHS-114, a highly selective cytolytic anti-CCR8
GlobeNewswireApr 24 22:02
CVS Favors Humira Copycats Hurting AbbVie's Market Share: Evercore
Seeking AlphaApr 17 21:26
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Acadia Healthcare (ACHC) and Coherus Biosciences (CHRS)
TipRanksApr 15 16:30
Unafraid of generic drugs entering the US market, ABBV.US (ABBV.US) Humira still accounts for nearly 100% of the share
Although a large number of discounted biosimilars entered the US market more than a year ago, ABBV.US (ABBV.US)'s blockbuster arthritis drug Humira (adalimumab) continues to maintain nearly 100% of the market share.
Zhitong FinanceApr 15 14:24
Investors in Coherus BioSciences (NASDAQ:CHRS) Have Unfortunately Lost 83% Over the Last Five Years
Yahoo FinanceApr 11 19:05
CNDT, CHRS and OM Are Among Materials Movers
Seeking AlphaApr 6 04:42
No Data
No Data